Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
Phase II Trial of Fluorouracil (5-FU), Leucovorin (LV), Irinotecan (CPT-11) and Bevacizumab (Anti-VEGF) in Previously Untreated Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bevacizumab may stop the growth of colorectal cancer by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus bevacizumab in treating patients who have advanced colorectal cancer.
研究概览
详细说明
OBJECTIVES: I. Determine the progression-free survival at 7 months of patients with previously untreated advanced colorectal cancer treated with fluorouracil, leucovorin calcium, irinotecan, and bevacizumab. II. Determine the response rate and overall survival of this patient population treated with this regimen. III. Determine the toxicity of this treatment regimen in these patients.
OUTLINE: This is a multicenter study. Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV once weekly for 4 weeks. Patients also receive bevacizumab IV over 30-90 minutes once every 2 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study within 1 year.
研究类型
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Pretoria、南非、0001
- Pretoria Academic Hospitals
-
-
-
-
-
San Juan、波多黎各、00927-5800
- MBCCOP - San Juan
-
San Juan、波多黎各、00927-5800
- Veterans Affairs Medical Center - San Juan
-
-
-
-
Arizona
-
Scottsdale、Arizona、美国、85259-5404
- CCOP - Scottsdale Oncology Program
-
-
California
-
Duarte、California、美国、91010-3000
- Cancer Center and Beckman Research Institute, City of Hope
-
Palo Alto、California、美国、94304
- Veterans Affairs Medical Center - Palo Alto
-
Stanford、California、美国、94305-5408
- Stanford University Medical Center
-
-
Colorado
-
Denver、Colorado、美国、80209-5031
- CCOP - Colorado Cancer Research Program, Inc.
-
-
Delaware
-
Wilmington、Delaware、美国、19899
- CCOP - Christiana Care Health Services
-
-
District of Columbia
-
Washington、District of Columbia、美国、20307-5000
- Walter Reed Army Medical Center
-
Washington、District of Columbia、美国、20060
- MBCCOP-Howard University Cancer Center
-
-
Florida
-
Gainesville、Florida、美国、32608-1197
- Veterans Affairs Medical Center - Gainsville
-
Miami、Florida、美国、33125
- Veterans Affairs Medical Center - Miami
-
Tampa、Florida、美国、33612-9497
- H. Lee Moffitt Cancer Center and Research Institute
-
Tampa、Florida、美国、33612
- Veterans Affairs Medical Center - Tampa (Haley)
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- Emory University Hospital - Atlanta
-
Decatur、Georgia、美国、30033
- Veterans Affairs Medical Center - Atlanta (Decatur)
-
-
Illinois
-
Chicago、Illinois、美国、60611-3013
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
-
Chicago、Illinois、美国、60611
- Veterans Affairs Medical Center - Lakeside Chicago
-
Decatur、Illinois、美国、62526
- CCOP - Central Illinois
-
Evanston、Illinois、美国、60201
- CCOP - Evanston
-
Peoria、Illinois、美国、61602
- CCOP - Illinois Oncology Research Association
-
Urbana、Illinois、美国、61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Indianapolis、Indiana、美国、46202-5289
- Indiana University Cancer Center
-
Indianapolis、Indiana、美国、46202
- Veterans Affairs Medical Center - Indianapolis (Roudebush)
-
-
Iowa
-
Cedar Rapids、Iowa、美国、52403-1206
- CCOP - Cedar Rapids Oncology Project
-
Des Moines、Iowa、美国、50309-1016
- CCOP - Iowa Oncology Research Association
-
Iowa City、Iowa、美国、52242-1009
- Holden Comprehensive Cancer Center at the University of Iowa
-
-
Kansas
-
Wichita、Kansas、美国、67218
- Veterans Affairs Medical Center - Wichita
-
-
Louisiana
-
New Orleans、Louisiana、美国、70121
- CCOP - Ochsner
-
New Orleans、Louisiana、美国、70112
- MBCCOP - LSU Health Sciences Center
-
-
Maryland
-
Baltimore、Maryland、美国、21231-2410
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Beth Israel Deaconess Medical Center
-
Boston、Massachusetts、美国、02111
- New England Medical Center Hospital
-
-
Michigan
-
Ann Arbor、Michigan、美国、48106
- CCOP - Ann Arbor Regional
-
Kalamazoo、Michigan、美国、49007-3731
- CCOP - Kalamazoo
-
-
Minnesota
-
Duluth、Minnesota、美国、55805
- CCOP - Duluth
-
Minneapolis、Minnesota、美国、55417
- Veterans Affairs Medical Center - Minneapolis
-
Minneapolis、Minnesota、美国、55455
- University of Minnesota Cancer Center
-
Rochester、Minnesota、美国、55905
- Mayo Clinic Cancer Center
-
Saint Louis Park、Minnesota、美国、55416
- CCOP - Metro-Minnesota
-
-
Nebraska
-
Omaha、Nebraska、美国、68131
- CCOP - Missouri Valley Cancer Consortium
-
Omaha、Nebraska、美国、68105
- Veterans Affairs Medical Center - Omaha
-
-
Nevada
-
Las Vegas、Nevada、美国、89106
- CCOP - Southern Nevada Cancer Research Foundation
-
-
New Jersey
-
East Orange、New Jersey、美国、07018-1095
- Veterans Affairs Medical Center - East Orange
-
Hackensack、New Jersey、美国、07601
- CCOP - Northern New Jersey
-
New Brunswick、New Jersey、美国、08901
- Cancer Institute Of New Jersey
-
-
New York
-
Albany、New York、美国、12208
- Veterans Affairs Medical Center - Albany
-
Bronx、New York、美国、10461
- Albert Einstein Comprehensive Cancer Center
-
Bronx、New York、美国、10466
- MBCCOP-Our Lady of Mercy Cancer Center
-
Brooklyn、New York、美国、11209
- Veterans Affairs Medical Center - Brooklyn
-
New York、New York、美国、10016
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
-
New York、New York、美国、10010
- Veterans Affairs Medical Center - New York
-
Rochester、New York、美国、14642
- University of Rochester Cancer Center
-
-
North Dakota
-
Fargo、North Dakota、美国、58122
- CCOP - Merit Care Hospital
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic Taussig Cancer Center
-
Cleveland、Ohio、美国、44106-5065
- Ireland Cancer Center
-
Cleveland、Ohio、美国、44106
- Veterans Affairs Medical Center - Cleveland
-
Columbus、Ohio、美国、43206
- CCOP - Columbus
-
Toledo、Ohio、美国、43623-3456
- CCOP - Toledo Community Hospital Oncology Program
-
-
Oklahoma
-
Tulsa、Oklahoma、美国、74136
- CCOP - Sooner State
-
-
Pennsylvania
-
Danville、Pennsylvania、美国、17822-2001
- CCOP - Geisinger Clinic and Medical Center
-
Philadelphia、Pennsylvania、美国、19111
- Fox Chase Cancer Center
-
Philadelphia、Pennsylvania、美国、19102-1192
- Hahnemann University Hospital
-
Philadelphia、Pennsylvania、美国、19104-4283
- University of Pennsylvania Cancer Center
-
Philadelphia、Pennsylvania、美国、19104-9104
- University of Pennsylvania Health Systems
-
Pittsburgh、Pennsylvania、美国、15213-3489
- University of Pittsburgh Cancer Institute
-
Pittsburgh、Pennsylvania、美国、15240
- Veterans Affairs Medical Center - Pittsburgh
-
Wynnewood、Pennsylvania、美国、19096
- CCOP - MainLine Health
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57105-1080
- CCOP - Sioux Community Cancer Consortium
-
-
Tennessee
-
Nashville、Tennessee、美国、37232-6838
- Vanderbilt-Ingram Cancer Center
-
Nashville、Tennessee、美国、37212
- Veterans Affairs Medical Center - Nashville
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792-6164
- University of Wisconsin Comprehensive Cancer Center
-
Madison、Wisconsin、美国、53705
- Veterans Affairs Medical Center - Madison
-
Marshfield、Wisconsin、美国、54449
- CCOP - Marshfield Medical Research and Education Foundation
-
Milwaukee、Wisconsin、美国、53226
- Medical College of Wisconsin
-
Milwaukee、Wisconsin、美国、53295
- Veterans Affairs Medical Center - Milwaukee (Zablocki)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS: Histologically confirmed advanced or metastatic adenocarcinoma of the colon and rectum Surgically unresectable disease Measurable disease Disease outside the prior radiotherapy port and/or progressive disease within the previously irradiated volume
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 No hemorrhagic events within the past 6 months Hepatic: Bilirubin normal SGOT normal INR no greater than 1.5 Renal: Creatinine no greater than 1.5 times upper limit of normal Cardiovascular: No thromboembolic events within the past 6 months Pulmonary: No evidence of pneumonia Other: No known hypersensitivity to recombinant humanized murine monoclonal antibodies No evidence of significant active infection (e.g., peritonitis or wound abscess) Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent sargramostim (GM-CSF) Chemotherapy: At least 12 months since prior fluorouracil-based adjuvant chemotherapy No prior adjuvant irinotecan Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 2 weeks since prior radiotherapy and recovered Surgery: See Disease Characteristics Other: No prior therapy for advanced disease No concurrent therapeutic anticoagulation except for low-dose coumadin for maintenance of indwelling catheters
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
合作者和调查者
调查人员
- 学习椅:Bruce J. Giantonio, MD、Presbyterian Medical Center
出版物和有用的链接
一般刊物
- Gray R, Giantonio BJ, O'Dwyer PJ, et al.: The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: the Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-825, 2003.
- Giantonio BJ, Chen HX, Catalano PJ, et al.: Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. [Abstract] J Clin Oncol 22 (Suppl 14): A-3017, 199s, 2004.
- Giantonio BJ, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB 3rd; Eastern Cooperative Oncology Group. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol. 2006 Sep;17(9):1399-403. doi: 10.1093/annonc/mdl161. Epub 2006 Jul 27.
- Giantonio BJ, Levy D, O'Dwyer PJ, et al.: Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1024, 2003.
- Giantonio BJ, Levy D, Catalano PJ, et al.: Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer (advCRC): a toxicity analysis of ECOG study E2200. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-503, 2002.
研究记录日期
研究主要日期
学习开始
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CDR0000068328
- ECOG-E2200
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.